CRISPR Therapeutics Dirección

Dirección controles de criterios 3/4

El CEO de CRISPR Therapeutics' es Sam Kulkarni , nombrado en Dec 2017, tiene una permanencia de 6.33 años. compensación anual total es $12.32M, compuesta por 5.9% salario y 94.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.48% de las acciones de la empresa, por valor de MX$390.42M. La antigüedad media del equipo directivo y de la junta directiva es de 5.4 años y 4.8 años, respectivamente.

Información clave

Sam Kulkarni

Chief Executive Officer (CEO)

US$12.3m

Compensación total

Porcentaje del salario del CEO	5.9%
Permanencia del CEO	6.4yrs
Participación del CEO	0.5%
Permanencia media de la dirección	5.5yrs
Promedio de permanencia en la Junta Directiva	4.9yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sam Kulkarni en comparación con los beneficios de CRISPR Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$217m
Dec 31 2023	US$12m	US$725k	-US$154m
Sep 30 2023	n/a	n/a	-US$354m
Jun 30 2023	n/a	n/a	-US$416m
Mar 31 2023	n/a	n/a	-US$524m
Dec 31 2022	US$21m	US$700k	-US$650m
Sep 30 2022	n/a	n/a	-US$681m
Jun 30 2022	n/a	n/a	-US$633m
Mar 31 2022	n/a	n/a	US$312m
Dec 31 2021	US$17m	US$670k	US$378m
Sep 30 2021	n/a	n/a	US$412m
Jun 30 2021	n/a	n/a	US$447m
Mar 31 2021	n/a	n/a	-US$392m
Dec 31 2020	US$9m	US$625k	-US$349m
Sep 30 2020	n/a	n/a	-US$211m
Jun 30 2020	n/a	n/a	US$20m
Mar 31 2020	n/a	n/a	US$46m
Dec 31 2019	US$16m	US$550k	US$67m
Sep 30 2019	n/a	n/a	-US$11m
Jun 30 2019	n/a	n/a	-US$200m
Mar 31 2019	n/a	n/a	-US$185m
Dec 31 2018	US$10m	US$518k	-US$165m
Sep 30 2018	n/a	n/a	-US$117m
Jun 30 2018	n/a	n/a	-US$91m
Mar 31 2018	n/a	n/a	-US$75m
Dec 31 2017	US$7m	US$405k	-US$68m

Compensación vs. Mercado: La compensación total de Sam($USD12.32M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD1.52M).

Compensación vs. Ingresos: La compensación de Sam ha sido consistente con los resultados de la empresa en el último año.

CEO

Sam Kulkarni (45 yo)

6.4yrs

Permanencia

US$12,322,196

Compensación

Dr. Samarth Kulkarni, Ph D., also known as Sam, has been an Independent Director of Repare Therapeutics Inc. since November 2019. Dr. Kulkarni serves as an Independent Non-Executive Director of Centessa Ph...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Samarth Kulkarni	CEO & Chairman	6.4yrs	US$12.32m	0.48% $ 350.5m
Raju Prasad	Chief Financial Officer	1.2yrs	US$5.91m	0.012% $ 8.6m
James Kasinger	General Counsel & Secretary	7yrs	US$3.51m	0.072% $ 52.5m
Shaun Foy	Founder	no data	sin datos	sin datos
Emmanuelle Charpentier	Co-Founder & Scientific Advisory Board Member	no data	sin datos	sin datos
Craig Mello	Scientific Founder & Advisory Board Member	no data	sin datos	sin datos
Chad Cowan	Scientific Founder	no data	sin datos	sin datos
Matthew Porteus	Scientific Founder & Advisory Board Member	no data	sin datos	sin datos
Daniel Anderson	Scientific Founder & Advisory Board Member	no data	sin datos	sin datos
Stephen Kennedy	Head of Technical Operations	4.6yrs	sin datos	sin datos
Susan Kim	Vice President of Corporate Communications & Investor Relations	no data	sin datos	sin datos
Megan Menner	Head of Human Resources	no data	sin datos	sin datos

5.5yrs

Permanencia media

48yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de CRSP N es experimentado (5.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Samarth Kulkarni	CEO & Chairman	5.9yrs	US$12.32m	0.48% $ 350.5m
Emmanuelle Charpentier	Co-Founder & Scientific Advisory Board Member	no data	sin datos	sin datos
Craig Mello	Scientific Founder & Advisory Board Member	no data	sin datos	sin datos
Matthew Porteus	Scientific Founder & Advisory Board Member	no data	sin datos	sin datos
Daniel Anderson	Scientific Founder & Advisory Board Member	no data	sin datos	sin datos
Douglas Treco	Lead Independent Director	3.9yrs	US$552.56k	0.0024% $ 1.7m
Ali Behbahani	Independent Director	9.1yrs	US$545.06k	0.00032% $ 233.3k
Katherine High	Independent Director	4.9yrs	US$532.56k	0% $ 0
Simeon George	Independent Director	9.1yrs	US$542.56k	0% $ 0
Stephen Elledge	Member of Scientific Advisory Board	no data	sin datos	sin datos
John Greene	Independent Director	4.9yrs	US$555.06k	0% $ 0
H. Fleming	Independent Director	2.9yrs	US$536.24k	0% $ 0

4.9yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de CRSP N se considera experimentada (4.8 años de antigüedad promedio).

CRISPR Therapeutics Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

Insufficient new directors

Insufficient new directors

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

Recent updates

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

Insufficient new directors

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

Full year 2022 earnings released: US$8.36 loss per share (vs US$4.97 profit in FY 2021)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

Investor sentiment deteriorated over the past week

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell Malignancies

Third quarter 2021 earnings released: US$1.67 loss per share (vs US$1.32 loss in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS US$10.01 (vs US$1.30 loss in 2Q 2020)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Presents New Data in 22 Patients with Greater Than 3 Months Follow-Up Post-Treatment with Investigational Crispr/Cas9 Gene-Editing Therapy

First quarter 2021 earnings released: US$1.51 loss per share (vs US$1.15 loss in 1Q 2020)

Full year 2020 earnings released: US$5.29 loss per share (vs US$1.23 profit in FY 2019)

Revenue misses expectations

CRISPR Therapeutics Appoints Philippe Drouet as Chief Commercial Officer

CRISPR Therapeutics and Vertex Present New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy, CTX001™ at American Society of Hematology Annual Meeting and Exposition, Together With Publication in the New England Journal of Medicine

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad